ggpp

Geranylgeranyl Pyrophosphate triammonium (GGPP triammonium) is a metabolite involved in protein geranylgeranylation, modulating endothelial cell proliferation and apoptosis during mouse embryonic angiogenesis. GGPP triammonium amplifies T(reg) differentiation by increasing IL-2 expression, improving DSS-induced colitis, useful in cancer research.

HGGPPS-IN-1 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). HGGPPS-IN-1 has an effective inhibitory effect on human geranyl geranyl pyrophosphate synthase (hGGPPS). HGGPPS-IN-1 can selectively induce apoptosis of multiple myeloma (MM) cells. HGGPPS-IN-1 showed anti-myeloma activity in vivo.

hGGPPS-IN-2 is an analogue of C-2 substituted thienopyrimidinyl bisphosphonates (C2-ThP-BPs) and is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 targets multiple myeloma (MM) cells, induces selective apoptosis, and shows anti-myeloma effects in vivo. It has shown anti-myeloma effects in vivo.

Compound 13h (hGGPPS-IN-3) is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS), characterized as a C-2-substituted thienopyrimidine-based bisphosphonate analogue (C2-ThP-BPs). It selectively induces apoptosis in multiple myeloma (MM) cells and demonstrates antimyeloma activity in vivo [1].

Digeranyl bisphosphonate (DGBP) is a potent geranylgeranyl pyrophosphate (GGPP) synthase inhibitor that impedes the geranyl pyrophosphorylation of Rac1 and induces autophagy without causing apoptosis.

Farnesyl pyrophosphate-D2 is the deuterium-labeled version of Farnesyl pyrophosphate (T73755) triammonium. This compound, also known as Farnesyl pyrophosphate (T73755) ammonium salt, is a 15-carbon isoprenoid and a metabolic intermediate in the mevalonate (MVA) pathway. It acts as an agonist of TRPM2 (TRP Channel), enabling the channel to open and allowing ion flow into cells. Additionally, Farnesyl pyrophosphate (T73755) ammonium salt serves as a crucial branching substrate for cholesterol synthesis, ubiquinone synthesis, protein prenylation, and the synthesis of geranylgeranyl pyrophosphate (GGPP).

CML-07-119 is a selective inhibitor of GGPP synthase (GGPPS) with an IC50 value of approximately 27 nM. It induces apoptosis and exhibits anticancer activity against acute myeloid leukemia (AML) cells, including those with TP53 mutations. CML-07-119 also suppresses tumor growth in AML mouse xenograft models and is applicable in AML research.

Farnesyl pyrophosphate (Farnesyl diphosphate), a 15-carbon isoprenoid from the mevalonate (MVA) pathway, functions as a metabolic intermediary and TRPM2 (TRP Channel) agonist, facilitating TRPM2 channel opening and ion influx. It is crucial in synthesizing cholesterol, ubiquinones, and geranyl-geranyl pyrophosphate (GGPP), and in protein farnesylation decoration [1].

Farnesyl pyrophosphate-D2 triammonium is a deuterium-labeled variant of farnesyl pyrophosphate triammonium. This 15-carbon isoprenoid serves as a metabolic intermediate in the mevalonate (MVA) pathway. Additionally, farnesyl pyrophosphate ammonium salt acts as an agonist for the TRPM2 (TRP Channel), facilitating ion entry into cells. It is also a crucial substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) production.

Gerfelin inhibits geranylgeranyl pyrophosphate synthase (GGPP synthase) activity, with an IC50 of 3.5 μg/mL.